Director Paolo Pucci filed a Form 144 notice of proposed sale of 138,700 shares of Replimune Group, Inc. common stock, with an approximate sale date of November 3, 2026, through Morgan Stanley Smith Barney LLC Executive Financial Services.

Key Highlights

  • Seller: Paolo Pucci, a Director of Replimune Group, Inc., is the person for whose account the securities are proposed to be sold.
  • Shares proposed for sale: 138,700 shares of Replimune Group common stock, with an aggregate market value of $2,833,987.75, according to the filing.
  • Acquisition method: The shares were acquired via stock option exercise from the issuer on November 3, 2026, with payment made in cash on the same date.
  • Shares outstanding: The filing reports 94,800,404 shares of common stock outstanding at the time of notice.
  • No prior sales: The filing indicates nothing to report for securities sold during the past three months by the same person.
  • Broker named: Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, is listed as the broker for the proposed transaction.

Pucci's Proposed Rule 144 Sale: Stock Option Exercise and Planned Disposition

According to the Form 144 filing submitted to the U.S. Securities and Exchange Commission, Paolo Pucci, identified as a Director of Replimune Group, Inc. (NASDAQ:REPL), provided notice of a proposed sale of 138,700 shares of the company's common stock. The notice is dated November 3, 2026, and lists the same date as the approximate date of sale.

The filing discloses that the 138,700 shares to be sold were acquired through a stock option exercise from the issuer on November 3, 2026, with the full purchase price paid in cash on that date. The aggregate market value of the shares proposed for sale is listed as $2,833,987.75. The filing states that there are 94,800,404 shares of Replimune Group common stock outstanding.

The filing reports no securities sold by Pucci during the three months preceding the notice date. The Form 144 also includes a representation, by virtue of Pucci's signature, that he does not know of any material adverse information regarding the current and prospective operations of Replimune Group that has not been publicly disclosed. The proposed sale is to be executed on the NASDAQ exchange through Morgan Stanley Smith Barney LLC Executive Financial Services.

What Was Disclosed

Replimune Group Director Paolo Pucci filed a Form 144 on November 3, 2026, disclosing a proposed sale of 138,700 common shares acquired via stock option exercise, with an aggregate market value of $2,833,987.75, to be executed through Morgan Stanley Smith Barney LLC on NASDAQ.